eLaws | eCases | United States Code | Federal Courts |
Home » Rulemaking » Quintiles - Comment

Quintiles - Comment

Document ID: FDA-2010-D-0529-0009
Document Type: Public Submission
Agency: Food And Drug Administration
Received Date: January 24 2011, at 12:00 AM Eastern Standard Time
Date Posted: January 31 2011, at 12:00 AM Eastern Standard Time
Comment Start Date: October 25 2010, at 12:00 AM Eastern Standard Time
Comment Due Date: January 24 2011, at 11:59 PM Eastern Standard Time
Tracking Number: 80bd0cb1
View Document:  View as format xml

View Comment

I am submitting comments on behalf of Quintiles Strategic Drug Development Unit, a group whose mission it is to develop innovative ways to develop drugs. For further information, I can be contacted at judy.abdalla@quintiles.com. Many thanks for considering our comments Judy Abdalla MD FRCPC

Attachments:

Quintiles - Comment

Title:
Quintiles - Comment

View Attachment: View as format msw12

Related Comments

    View All
Total: 15
Novo Nordisk Inc. - Comment
Public Submission    Posted: 01/18/2011     ID: FDA-2010-D-0529-0003

Jan 24,2011 11:59 PM ET
Amgen, Inc. - Comment
Public Submission    Posted: 01/31/2011     ID: FDA-2010-D-0529-0007

Jan 24,2011 11:59 PM ET
Bausch+Lomb - Comment
Public Submission    Posted: 01/31/2011     ID: FDA-2010-D-0529-0008

Jan 24,2011 11:59 PM ET
Quintiles - Comment
Public Submission    Posted: 01/31/2011     ID: FDA-2010-D-0529-0009

Jan 24,2011 11:59 PM ET
International Society for CNS Clinical Trials and Methodology (ISCTM) - Comment
Public Submission    Posted: 01/31/2011     ID: FDA-2010-D-0529-0010

Jan 24,2011 11:59 PM ET